neuromuscular diseases for which a high vector dose is required with natural AAVs, the team demonstrated the efficacy of the new capsid in muscle at a lower dose and without penetrating the liver.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback